ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

Tuesday, July 18, 2017

Submitted by

Ruben Osnabrugge

Source

Source Name: New England Journal of Medicine

Source URL: http://www.nejm.org/doi/full/10.1056/NEJMoa1707278

Author(s)

Charles V. Pollack, Jr., Paul A. Reilly, Joanne van Ryn, John W. Eikelboom, Stephan Glund, Richard A. Bernstein, Robert Dubiel, Menno V. Huisman, Elaine M. Hylek, Chak-Wah Kam, Pieter W. Kamphuisen, Jörg Kreuzer, Jerrold H. Levy, Gordon Royle, Frank W. Sellke, Joachim Stangier, Thorsten Steiner, Peter Verhamme, Bushi Wang, Laura Young, and Jeffrey I. Weitz

In this study, the Dabigatran reversal-drug Idarucizumab was tested. 503 patients were enrolled, of whom 202 had to undergo an urgent procedure. Of the patients requiring an urgent procedure, the median time of initiation of the procedure was 1.6 hours, and at that time periprocedural hemostasis was assessed as normal in 93.4% of the patients. At 90 days, thrombotic events had occurred in 7.4% of the patients requiring an urgent procedure and the mortality rate was 18.9%. The results of this study show that Idarucizumab is a rapid and effective reversal drug for the effects of Dabigatran in case of the need for urgent surgery. As Dabigatran is increasingly being used in patients with atrial fibrillation, the availability of Idarucizumab is important.